Amgen Analyst Price Targets

Wall Street analyst price targets and consensus rating for Amgen (AMGN).

Price Target Range — 8 Quarters

Analyst Consensus — 22 Analysts

8Buy

12Hold

2Sell

Consensus RatingNeutral# Analysts22Avg. Consensus PT$383Upside to Avg. PT-5.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	Scotiabank	Louise Chen	PT Raise	Sector Outperform	$450→$500
Sep 10, 2026	HSBC	Morten Herholdt	Downgrade	Buy→Hold	$445→$425
Sep 8, 2026	BMO Capital	Evan David Seigerman	Downgrade	Outperform→Market Perform	$450
Sep 8, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Neutral	$400
Sep 4, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$400→$435
Aug 20, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$427→$457
Aug 19, 2026	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$351→$362
Aug 19, 2026	Argus Research	Jasper Hellweg	PT Raise	Buy	$375→$460
Aug 18, 2026	Mizuho	Salim Syed	PT Raise	Neutral	$303→$352
Aug 18, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Neutral	$350→$400
Aug 14, 2026	Barclays	Emily Field	PT Raise	Equal-Weight	$360→$380
Aug 10, 2026	Guggenheim	Vamil Divan	PT Raise	Neutral	$343→$388
Aug 7, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$345→$405
Aug 6, 2026	Bernstein	Courtney Breen	PT Raise	Market Perform	$335→$345
Aug 5, 2026	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$333→$351
Aug 5, 2026	Baird	Brian Skorney	PT Raise	Underperform	$215→$230
Aug 5, 2026	Canaccord Genuity	Gary Nachman	PT Raise	Hold	$366→$384
Aug 5, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Underperform	$312→$317
Aug 5, 2026	Goldman Sachs	Salveen Richter	PT Raise	Buy	$427→$450
Aug 5, 2026	UBS	Michael Yee	PT Raise	Buy	$420→$440

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $500

Scotiabank analyst Louise Chen maintains Amgen (NASDAQ:AMGN) with a Sector Outperform and raises the price target from $450 to $500.

Benzinga Newsdesk

Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data

Amgen's Phase 3 study shows dazodalibep significantly improves systemic disease activity in adults with Sjögren's disease.

Vandana Singh

PRO
HSBC Downgrades Amgen to Hold, Lowers Price Target to $425

HSBC analyst Morten Herholdt downgrades Amgen (NASDAQ:AMGN) from Buy to Hold and lowers the price target from $445 to $425.

Benzinga Newsdesk

This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday

Analysts downgraded BioNTech, Gulfport Energy, Amgen and Best Buy; price targets fell for BioNTech and Gulfport.

Avi Kapoor

PRO
BMO Capital Downgrades Amgen to Market Perform, Maintains Price Target to $450

BMO Capital analyst Evan David Seigerman downgrades Amgen (NASDAQ:AMGN) from Outperform to Market Perform and maintains the price target from $450 to $450.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Neutral on Amgen, Maintains $400 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Amgen (NASDAQ:AMGN) with a Neutral and maintains $400 price target.

Benzinga Newsdesk

Amgen Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Amgen Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $500

Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data

PRO
HSBC Downgrades Amgen to Hold, Lowers Price Target to $425

This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday

PRO
BMO Capital Downgrades Amgen to Market Perform, Maintains Price Target to $450

PRO
Cantor Fitzgerald Reiterates Neutral on Amgen, Maintains $400 Price Target

People Also Watch

People Also Watch

Amgen Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Amgen Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROScotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $500

Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data

PROHSBC Downgrades Amgen to Hold, Lowers Price Target to $425

This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday

PROBMO Capital Downgrades Amgen to Market Perform, Maintains Price Target to $450

PROCantor Fitzgerald Reiterates Neutral on Amgen, Maintains $400 Price Target

People Also Watch

People Also Watch

PRO
Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $500

PRO
HSBC Downgrades Amgen to Hold, Lowers Price Target to $425

PRO
BMO Capital Downgrades Amgen to Market Perform, Maintains Price Target to $450

PRO
Cantor Fitzgerald Reiterates Neutral on Amgen, Maintains $400 Price Target